A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn's Disease
Phase of Trial: Phase III
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms GEMINI-LTS
- Sponsors Takeda Oncology
- 06 Feb 2018 Status changed from active, no longer recruiting to completed.
- 01 Feb 2018 This trial has been completed in Estonia, (End date: 2017-10-31) according to European Clinical Trials Database record.
- 11 Jul 2017 This trial has been completed in Austria, according to European Clinical Trials Database record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History